secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alaunos Therapeutics, Inc. (TCRT)
CIK:        0001107421
Form:       8-K
Filed at:   2025-07-02T23:59:59+00:00
Accession:  0000950170-25-093263
Event type: leadership
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01, 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Alaunos Therapeutics CEO resigns; Holger Weis appointed; audit committee shortfall triggers Nasdaq notice
--------------------------------------------------------------------------------

- Dale Curtis Hogue Jr. resigned as CEO and director effective July 1, 2025; no disagreement.
- Holger Weis appointed CEO July 2, 2025; $275,000 base salary; option for 130,000 shares at $5.06.
- Weis resigned from audit and compensation committees, causing non-compliance with Nasdaq Rule 5605(c); company intends to use 180-day grace period.
- Hogue entered consulting agreement at $250/hour for strategic advisory services.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1107421/000095017025093263/0000950170-25-093263-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1107421/000095017025093263/tcrt-20250701.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-093263

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer